Education
About Us
Working with TipRanks
Follow Us
COMPASS Pathways (DE:5Y6)
FRANKFURT:5Y6
5Y6 Stock Chart & Stats
€5.50
-€0.46(-9.79%)
At close: 4:00 PM EST
€5.50
-€0.46(-9.79%)
Day’s Range― - ―
52-Week Range€2.10 - €7.65
Previous CloseN/A
Volume0.00
Average Volume (3M)288.00
Market Cap
$614.23M
Enterprise Value€563.50M
Total Cash (Recent Filing)$185.94M
Total Debt (Recent Filing)$35.18M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding113,517,044
10 Day Avg. Volume113
30 Day Avg. Volume288
Financial Highlights & Ratios
PEG Ratio1.91
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-2.14
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.44
Forecast
1Y Price Target
$19.00Price Target Upside245.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.54
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyConfirmatory Phase 3 trials met primary endpoints, demonstrating rapid and durable antidepressant effects with an optional second dose increasing remission rates, strengthening the case for regulatory approval and market differentiation.
Commercial Adoption And PartnershipsStrategic collaborations with specialized interventional psychiatry networks and plans to leverage existing treatment infrastructure position the therapy to scale delivery and accelerate provider adoption.
Regulatory And Reimbursement PathwayRegulatory receptivity to pragmatic trial designs combined with new procedural billing codes for monitored sessions creates a clearer framework for reimbursement and controlled clinical delivery, improving commercial viability.
Bears Say
Comparator Efficacy And Retreatment NeedSigns that a low-dose control showed clinical activity and that many patients may require retreatment could complicate regulatory interpretation and reduce perceived advantage versus competing therapies.
Execution And Operational RiskChallenges in building clinic infrastructure and managing regulatory sequencing create execution risk that could delay rollout and restrict early patient access if operational milestones are missed.
Financing And Dilution RiskHigh cash burn and a limited cash runway increase the likelihood of future fundraising, which could lead to dilution or constrain investment in commercialization efforts.
COMPASS Pathways News
5Y6 FAQ
What was COMPASS Pathways’s price range in the past 12 months?
COMPASS Pathways lowest stock price was €2.10 and its highest was €7.65 in the past 12 months.
What is COMPASS Pathways’s market cap?
COMPASS Pathways’s market cap is $614.23M.
When is COMPASS Pathways’s upcoming earnings report date?
COMPASS Pathways’s upcoming earnings report date is May 07, 2026 which is in 55 days.
How were COMPASS Pathways’s earnings last quarter?
Currently, no data Available
Is COMPASS Pathways overvalued?
According to Wall Street analysts COMPASS Pathways’s price is currently Undervalued.
Does COMPASS Pathways pay dividends?
COMPASS Pathways does not currently pay dividends.
What is COMPASS Pathways’s EPS estimate?
COMPASS Pathways’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COMPASS Pathways have?
COMPASS Pathways has 113,517,044 shares outstanding.
What happened to COMPASS Pathways’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of COMPASS Pathways?
Currently, no hedge funds are holding shares in DE:5Y6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
COMPASS Pathways Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.00 (245.39% Upside)
$19.00 (245.39% Upside)
Blogger Sentiment
Neutral
DE:5Y6 Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Positive
20 days / 200 days
Momentum
83.42%
12-Months-Change
Fundamentals
Return on Equity
-172.50%
Trailing 12-Months
Asset Growth
3.34%
Trailing 12-Months
Company Description
COMPASS Pathways
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
5Y6 Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with significant progress in clinical trials, regulatory interactions, and launch preparations. While there was a decrease in cash reserves, the company maintains a strong cash position with a runway into 2027.View all DE:5Y6 earnings summaries5Y6 Stock 12 Month Forecast
Average Price Target
€19.00
▲(245.39% Upside)
Technical Analysis
Cross Country Healthcare
―
Oncology Institute
―
Talkspace
―
InnovAge Holding
―
Agilon Health
―
Options Prices
Currently, No data available
---